Download presentation
Presentation is loading. Please wait.
1
CD40 and OX40 ligand are increased on stimulated asthmatic airway smooth muscle
Janette K. Burgess, PhD, Anita E. Blake, BSc, Sarah Boustany, MSc, Peter R.A. Johnson, PhD, Carol L. Armour, PhD, Judith L. Black, MBBS, PhD, Nicholas H. Hunt, PhD, J. Margaret Hughes, PhD Journal of Allergy and Clinical Immunology Volume 115, Issue 2, Pages (February 2005) DOI: /j.jaci Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions
2
Fig 1 Induction of cell surface expression of CD40, OX40L and ICAM after stimulation with TNF-α, IL-1β, IL-4, or IL-13. A, Representative flow cytometric histograms from a person without asthma. B, MFI of CD40 expression. C, MFI of OX40L. TNF-α and IL-1β, n=6; IL-4 and IL-13, n=3 for asthmatic (A) and nonasthmatic (NA). Journal of Allergy and Clinical Immunology , DOI: ( /j.jaci ) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions
3
Fig 2 Induction of cell surface expression of CD40 (A) and OX40L (B) after stimulation with TNF-α with or without IL-1β, IL-4, or IL-13. The data presented in Fig 1 for TNF-α treatment are included here for comparative purposes. TNF-α and TNF-α+IL-1β, n=6; TNF-α+IL-4 and TNF-α+IL-13, n=3 for asthmatic (A) and nonasthmatic (NA). Journal of Allergy and Clinical Immunology , DOI: ( /j.jaci ) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions
4
Fig 3 Immunohistochemical detection and colocalization of CD40 (red) and OX40L (green) after stimulation with TNF-α and IL-1β alone or in combination in (A) nonasthmatic cells in culture and (B) tissue sections from a patient without asthma. H&E, Hematoxylin and eosin. Journal of Allergy and Clinical Immunology , DOI: ( /j.jaci ) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions
5
Fig 4 Inhibition of cell surface expression of CD40 (A) and OX40L (B) after treatment with TNF-α with IL-1β ± indomethacin, PGE2, or 8-bromo–cAMP. The data presented in Fig 2 for TNF-α with or without IL-1β treatment are included here for comparative purposes. TNF-α and TNF-α+IL-1β, n=6; all other treatments, n=3 for asthmatic and nonasthmatic. 8-Bromo, 8-Bromo-cAMP; Indo, indomethacin. Journal of Allergy and Clinical Immunology , DOI: ( /j.jaci ) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.